Chaoting Zhou

Mar 6, 2024 | biorxiv.org | Kyung Ku Jang |Defne Ercelen |Chaoting Zhou |Sakteesh Gurunathan

AbstractBackground & Aims: Despite increasing therapeutic options in the treatment of ulcerative colitis (UC), achieving disease remission remains a major clinical challenge. Nonresponse to therapy is common and clinicians have little guidance in selecting the optimal therapy for an individual patient. This study examined whether patient-derived materials could predict individual clinical responsiveness to the Janus kinase (JAK) inhibitor, tofacitinib, prior to treatment initiation.

Feb 1, 2024 | mdpi.com | Alex Li |Peiwei Li |Chaoting Zhou |Thomas Kluz

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.